Patients without sarcopenia at baseline but who had high IP-10 levels at baseline or high IP-10 ratios after 1 year exhibited several distinguishing characteristics, which were as follows: high ALBI grade, low BCAA, low BTR, low platelet counts, more patients opting for transarterial chemoembolization (TACE) as treatment for primary HCC, and recurrence beyond up to seven criteria during the 3-year follow-up period (Table 4). This evidence concerns the gene CXCL10 and sarcopenia.